Related references
Note: Only part of the references are listed.Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid Focus on Antibacterial Agents
Keith A. Rodvold et al.
CLINICAL PHARMACOKINETICS (2011)
Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions
Yigong Ge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Pharmacokinetic-Pharmacodynamic Considerations in the Design of Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia Studies: Look before You Leap!
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2010)
Three Decades of beta-Lactamase Inhibitors
Sarah M. Drawz et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Update on the treatment of Pseudomonas aeruginosa pneumonia
Ali A. El Solh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Epidemiology of Healthcare-Associated Pneumonia (HCAP)
Marya D. Zilberberg et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Alveolar concentrations of pipeyacillin/tazobactam administered in continuous infusion to patients with ventilatoy-associated pneumonia
Emmanuel Boselli et al.
CRITICAL CARE MEDICINE (2008)
Pseudomonas aeruginosa:: resistance and therapeutic options at the turn of the new millennium
N. Mesaros et al.
CLINICAL MICROBIOLOGY AND INFECTION (2007)
Estimating health care-associated infections and deaths in US hospitals, 2002
R. Monina Klevens et al.
PUBLIC HEALTH REPORTS (2007)
The antimicrobial therapy puzzle: Could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?
Federico Pea et al.
CLINICAL INFECTIOUS DISEASES (2006)
Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia
E Boselli et al.
INTENSIVE CARE MEDICINE (2004)
Share Paper
